Stratos Wealth Partners LTD. Takes $241,000 Position in Anavex Life Sciences Corp. (NASDAQ:AVXL)

Stratos Wealth Partners LTD. bought a new position in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 22,457 shares of the biotechnology company’s stock, valued at approximately $241,000.

Other hedge funds have also added to or reduced their stakes in the company. Orion Capital Management LLC increased its stake in Anavex Life Sciences by 666.7% in the third quarter. Orion Capital Management LLC now owns 11,500 shares of the biotechnology company’s stock valued at $65,000 after purchasing an additional 10,000 shares in the last quarter. PVG Asset Management Corp acquired a new stake in shares of Anavex Life Sciences in the 3rd quarter valued at about $74,000. Atria Investments Inc bought a new stake in Anavex Life Sciences in the 3rd quarter valued at about $76,000. BNP Paribas Financial Markets raised its stake in Anavex Life Sciences by 97.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 15,074 shares of the biotechnology company’s stock worth $86,000 after buying an additional 7,421 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in Anavex Life Sciences by 64.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 16,309 shares of the biotechnology company’s stock worth $93,000 after acquiring an additional 6,366 shares in the last quarter. 31.55% of the stock is currently owned by institutional investors.

Anavex Life Sciences Stock Performance

Shares of NASDAQ AVXL opened at $8.47 on Friday. The firm’s 50-day simple moving average is $9.94 and its 200 day simple moving average is $7.70. The stock has a market cap of $718.43 million, a price-to-earnings ratio of -16.29 and a beta of 0.69. Anavex Life Sciences Corp. has a fifty-two week low of $3.25 and a fifty-two week high of $14.44.

Anavex Life Sciences (NASDAQ:AVXL) last announced its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.03. On average, sell-side analysts predict that Anavex Life Sciences Corp. will post -0.73 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on AVXL shares. D. Boral Capital restated a “buy” rating and set a $46.00 price objective on shares of Anavex Life Sciences in a report on Wednesday. HC Wainwright restated a “buy” rating and set a $42.00 price target on shares of Anavex Life Sciences in a research note on Tuesday, January 28th.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.